Antibiotic resistance in general is on the rise worldwide, but one especially troubling example is the rise in resistant strains of E. coli, the bacteria that cause more than 80% of UTIs. The Center for Disease Dynamics, Economics & Policy (CDDEP) reports that in 2014, the most commonly used class of antibiotics for UTI, fluoroquinolones, had 35% resistance to E. coli. The resistance had more than doubled in the last decade. Spero is developing novel agents to treat these resistant bacteria.
SPR994: Our most advanced compound is SPR994, an oral beta-lactam that we are developing as a broad spectrum oral antibiotic for treatment of complicated urinary tract infections (cUTI) to help patients avoid hospitalizations (stay home) and/or transition patients home after IV therapy (get home).
- Offers a broad range of activity against a wide variety of multidrug-resistant Gram-negative, Gram-positive and anaerobic bacteria. In in vitro studies, SPR994 demonstrated potent antibacterial activity against Gram-negative bacteria, including ESBL-producing E. coli and ESBL-producing Klebsiella pneumoniae.
- Convenient dosing regimen to avoid hospitalization. Unlike other medications to treat these resistance bacteria which are only available as intravenous infusions, SPR994 is an orally administered tablet, avoiding the need for intravenous antibiotics for an otherwise healthy or stable patient and assist with avoiding costs of hospitalization and/or shorten length of stay.
- Potential for convenient IV-to-oral transition to assist with getting patients out of the hospital and reduce length of stay. SPR994’s unique oral formulation will enable patients who begin IV treatment in the hospital setting to transition to oral dosing of SPR994 either in hospital or upon patient discharge for convenient home-based care.